Christopher J. Ott

The paper introduces molecular COUPLrs to systematically target protein complexes, identifying new glue classes and their interactions in cancer cell lines.

This paper identifies BisRoc, a dimeric rocaglate ligand that suppresses translation more potently and specifically than monomeric RocA by promoting multivalent eIF4A-RNA assembly.

The paper shows that BRD4 and p300/CBP regulate CDK9 activity, linking enhancer complex formation with promoter-proximal Pol II pausing.

This study shows that CDK9 degradation with KI-CDK9d-32 is more effective than inhibition in disrupting MYC transcriptional networks and causes MYC downregulation and nucleolar destabilization.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

This study identifies CoA metabolism dysregulation as a mechanism of resistance to HAT inhibitors in AML, revealing a potential class-wide vulnerability for anti-cancer therapies targeting HATs.

The paper constructs transcriptional regulatory networks to identify master transcription factors in cell types and applies the method to chronic lymphocytic leukemia, showing efficacy of targeting these factors.